Xenitra Posts A$0.8 Million Operating Cash Flow as OTC and OPAL Sales Gain Traction

Cash Flow Turnaround Signals Strategic Shift

Xenitra Limited (ASX:XEN) has delivered a marked operational turnaround in the June quarter, reporting positive operating cash flow of A$0.8 million. This represents a dramatic improvement of A$2.13 million from the prior quarter’s A$1.33 million outflow and a A$2.46 million swing from the same period last year. The company attributes this to a deliberate shift away from low-margin, working-capital intensive nutritionals towards higher-margin OTC medicines and its blockchain-enabled OPAL tokenised sales ecosystem.

Customer receipts declined 32% quarter-on-quarter to A$5.33 million, reflecting reduced legacy trading volumes and sales timing. However, product manufacturing and operating payments plunged 56%, underscoring a leaner cost structure and improved cash conversion. The resulting cash trading contribution of A$1.59 million comfortably funded operating expenses and produced positive net operating cash flow.

OPAL Ecosystem Gains Momentum with Rapid Distributor Growth

The OPAL ecosystem, Xenitra’s blockchain-enabled sales and loyalty platform, has validated its commercial potential. Since its April launch, OPAL tokenised sales of the EZZ Life Science product range have exceeded A$1.5 million, with over 500 distribution partners onboarded. This rapid uptake highlights growing distributor engagement and customer acceptance of the token-linked sales model, which aims to enhance product authenticity, repeat purchases, and customer loyalty.

Biomiq Skincare, an Australian brand specialising in acne, minor skin conditions, and anti-ageing products, joined OPAL as the second major brand partner with a scheduled launch in August 2026. This four-year exclusive distribution deal targets minimum product sales of A$5 million, testing OPAL’s scalability across multiple brands and product categories.

OTC Platform Operationalised with Hong Kong Acquisition and Major Deal

In April, Xenitra completed the acquisition of Hong Kong Fukang Trading Co., including a pharmaceutical wholesale licence and ecommerce infrastructure, establishing a compliant platform for cross-border OTC medicine sales into Greater China. The OTC division is designed to deliver significantly higher gross margins than legacy nutritionals through regulated market access and specialised product offerings.

Post-quarter, Xenitra secured a three-year procurement agreement with Kangsheng Hong Kong International Trading Limited, expected to generate at least A$12 million in sales. Kangsheng’s ecommerce and retail pharmacy network provides a critical distribution channel for Xenitra’s OTC products, marking the division’s transition from platform build-out to commercial execution. Initial orders are anticipated in Q1 FY27 following operational onboarding. This deal complements Xenitra’s existing nutritionals and OPAL sales pillars, broadening its revenue base.

Restructuring Drives Cost Efficiency and Margin Improvement

Underlying the improved cash flow is a comprehensive restructuring program initiated throughout FY26. Xenitra has simplified its corporate structure, reduced fixed infrastructure, and concentrated resources on its three strategic pillars: nutritionals, OTC medicines, and OPAL tokenised sales. This effort has delivered approximately A$1 million in annualised savings, with Australian headcount and office costs trimmed and non-core joint ventures wound up or resolved.

Gross profit margin improved sharply to approximately 16% in Q4 from below 5% in Q3, reflecting the higher-margin sales mix. Despite lower total sales, gross profit increased by around A$0.81 million. The company’s focus on disciplined sales selection and working capital management in nutritionals has maintained a stable base while enabling growth in more profitable segments.

Outlook and Near-Term Priorities

Entering FY27, Xenitra holds A$3.79 million in cash, more than double the prior quarter, supported by positive operating cash flow and net financing inflows. The company plans to accelerate OTC commercialisation under the Kangsheng agreement, launch Biomiq Skincare via OPAL, and continue scaling the tokenised sales ecosystem. It will also execute the Danone product supply agreement under its nutritionals pillar with disciplined margin focus.

While the restructuring has improved cash flow and margins, the timing and scale of OTC order flow remain subject to regulatory and market conditions. Xenitra’s ability to convert strategic progress into sustainable profitability will hinge on execution across its three pillars and ongoing cost control.